Swetha Kambhampati Selected Research

lysine(6)- glutaryl- 2- (hydroxymethyl)anthraquinone LHRH (T 98)

12/2022

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Swetha Kambhampati Research Topics

Disease

5	Multiple Myeloma 12/2022 - 01/2020
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 06/2022 - 01/2021
2	Infections 12/2022 - 01/2021
2	Lymphoma (Lymphomas) 01/2021 - 01/2021
1	Lymphopenia (Lymphocytopenia) 12/2022
1	Neutropenia 12/2022
1	Hodgkin Disease (Hodgkin's Disease) 10/2022
1	Macrophage Activation Syndrome 12/2021
1	Cytokine Release Syndrome 01/2021
1	Fever (Fevers) 01/2021
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021
1	Residual Neoplasm 01/2021
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2021
1	Hematologic Neoplasms (Hematological Malignancy) 01/2020
1	Adenoma (Adenomas) 01/2020
1	Abdominal Obesity 01/2020
1	Neoplasms (Cancer) 01/2020
1	Hepatocellular Carcinoma (Hepatoma) 01/2019
1	Fibrosis (Cirrhosis) 01/2019
1	Barrett Esophagus (Barrett's Esophagus) 01/2019
1	Ileus 11/2016
1	Pancreatitis 12/2014
1	Rupture 12/2012
1	Atherosclerosis 12/2012
1	Atherosclerotic Plaque (Atheroma) 12/2012
1	Inflammation (Inflammations) 12/2012

Drug/Important Bio-Agent (IBA)

4	Biomarkers (Surrogate Marker)IBA 01/2021 - 12/2012
3	Chimeric Antigen ReceptorsIBA 12/2022 - 01/2021
3	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 12/2022 - 01/2021
2	B-Cell Maturation AntigenIBA 12/2022 - 01/2021
2	Proteasome InhibitorsIBA 01/2021 - 01/2020
1	lysine(6)- glutaryl- 2- (hydroxymethyl)anthraquinone LHRH (T 98)IBA 12/2022
1	avelumabIBA 10/2022
1	polatuzumab vedotinIBA 06/2022
1	carboxyl radical (COO-)IBA 01/2021
1	tocilizumab (atlizumab)FDA Link 01/2021
1	carfilzomibIBA 01/2021
1	ofatumumab FDA Link 01/2021
1	Rituximab (Mabthera)FDA Link 01/2021
1	Bendamustine Hydrochloride FDA Link 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021
1	Etoposide (VP 16)FDA LinkGeneric 01/2021
1	Bispecific AntibodiesIBA 01/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	Caffeine (No Doz)FDA LinkGeneric 01/2020
1	venetoclaxIBA 01/2020
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2020
1	NivolumabIBA 01/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 12/2014
1	Pharmaceutical PreparationsIBA 12/2012
1	CytokinesIBA 12/2012
1	GelsIBA 12/2012
1	SteroidsIBA 12/2012

Therapy/Procedure

5	Therapeutics 12/2022 - 12/2012
1	Salvage Therapy 01/2022
1	Radiotherapy 01/2022
1	Cell Transplantation 01/2021
1	Immunotherapy 01/2021
1	Transplantation 01/2021
1	Stem Cell Transplantation 01/2021
1	Conservative Treatment 12/2014